Connect with us
Financial Press


: Gilead coronavirus drug use expanded to include moderate cases

Gilead Sciences Inc.

said late Friday it received emergency U.S. approval for treatment for COVID-19 patients with a moderate form of the disease.

Gilead said the Food and Drug Administration expanded it emergency use of the antiviral drug Veklury, also known as remdesivir, to treat moderate cases of COVID-19 in hospitals, instead of just severe cases.

The expansion is based on data from a late-stage clinical trial that showed that COVID-19 patients given Veklury along with standard treatment were 65% more likely to show an improvement than patients given standard treatment alone, Gilead said.

Shares of Gilead were up 0.8% after hours, following a 0.4% decline in the regular session to close at $65.26. Gilead shares are up 0.4% for the year, compared with an 8.6% gain in the S&P 500 index

Written By

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles


NewsWatch Published: Sept. 18, 2020 at 5:00 p.m. ET MARKETWATCH FRONT PAGE History isn’t repeating itself when it comes to the highflying technology stocks...


Bond Report Last Updated: Sept. 18, 2020 at 4:58 p.m. ET First Published: Sept. 18, 2020 at 8:39 a.m. ET U.S. Treasury yields edged...


The Fed Published: Sept. 18, 2020 at 4:34 p.m. ET ‘How can it possibly be this fragile?’ Minneapolis Fed President asks Minneapolis Fed President...


U.S. stock indexes closed lower Friday, notching a third straight weekly loss, amid uncertainty about a fresh round of fiscal stimulus from Washington, concerns...